Paul J Declerck

List of Publications by Citations

236 papers	6,043 citations	41 h-index	63 g-index
260 ext. papers	6,648 ext. citations	7 avg, IF	5.86 L-index

#	Paper	IF	Citations
236	The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent. *FASEB Journal*, **2002**, 16, 147-54	0.9	238
235	Activated thrombin activatable fibrinolysis inhibitor levels are associated with the risk of cardiovascular death in patients with coronary artery disease: the AtheroGene study. *Journal of Thrombosis and Haemostasis*, **2009**, 7, 49-57	15.4	156
234	Age-dependent spontaneous coronary arterial thrombosis in transgenic mice that express a stable form of human plasminogen activator inhibitor-1. *Circulation*, **2002**, 106, 491-6	16.7	148
233	Effectiveness of the electronic cigarette: An eight-week Flemish study with six-month follow-up on smoking reduction, craving and experienced benefits and complaints. *International Journal of Environmental Research and Public Health*, **2014**, 11, 11220-48	4.6	138
232	Host-derived plasminogen activator inhibitor-1 (PAI-1) concentration is critical for in vivo tumoral angiogenesis and growth. *Oncogene*, **2004**, 23, 6986-90	9.2	133
231	Comparison of random and oriented immobilisation of antibody fragments on mixed self-assembled monolayers. *Journal of Immunological Methods*, **2006**, 312, 167-81	2.5	126
230	Realization and characterization of porous gold for increased protein coverage on acoustic sensors. *Analytical Chemistry*, **2004**, 76, 4299-306	7.8	106
229	Mechanisms contributing to the conformational and functional flexibility of plasminogen activator inhibitor-1. *Nature Structural Biology*, **1995**, 2, 891-7		99
228	Three decades of research on plasminogen activator inhibitor-1: a multifaceted serpin. *Seminars in Thrombosis and Hemostasis*, **2013**, 39, 356-64	5.3	98
227	Plasminogen activator inhibitor-1 modulates adipocyte differentiation. *American Journal of Physiology - Endocrinology and Metabolism*, **2006**, 290, E103-E113	6	92
226	Plasminogen activator inhibitor 1. Structure of the native serpin, comparison to its other conformers and implications for serpin inactivation. *Journal of Molecular Biology*, **2000**, 297, 683-95	6.5	90
225	The Biochemistry, Physiology and Pathological roles of PAI-1 and the requirements for PAI-1 inhibition in vivo. *Thrombosis Research*, **2012**, 130, 576-85	8.2	83
224	The structural basis for the pathophysiological relevance of PAI-I in cardiovascular diseases and the development of potential PAI-I inhibitors. *Thrombosis and Haemostasis*, **2004**, 91, 425-37	7	79
223	Development of a genotype 325-specific proCPU/TAFI ELISA. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2003**, 23, 1122-7	9.4	76
222	Substrate behavior of plasminogen activator inhibitor-1 is not associated with a lack of insertion of the reactive site loop. *Biochemistry*, **1996**, 35, 7474-81	3.2	76
221	The Language of Biosimilars: Clarification, Definitions, and Regulatory Aspects. *Drugs*, **2017**, 77, 671-677	12.1	73
220	Immunoassay of Murine t-PA, u-PA and PAI-1 Using Monoclonal Antibodies Raised in Gene-inactivated Mice. *Thrombosis and Haemostasis*, **1995**, 74, 1305-1309	7	73

219	Purification and characterization of natural and recombinant human plasminogen activator inhibitor-1 (PAI-1). *FEBS Journal*, **1988**, 175, 531-40		65
218	PAI-1 mediates the antiangiogenic and profibrinolytic effects of 16K prolactin. *Nature Medicine*, **2014**, 20, 741-7	50.5	64
217	Hormonal Control of Plasminogen Activator Inhibitor-1 Gene Expression and Production in Human Adipose Tissue: Stimulation by Glucocorticoids and Inhibition by Catecholamines. *Journal of Clinical Endocrinology and Metabolism*, **1999**, 84, 4097-4105	5.6	64
216	Neutralization of plasminogen activator inhibitor-1 inhibitory properties: identification of two different mechanisms. *BBA - Proteins and Proteomics*, **1997**, 1337, 257-66		63
215	Thrombin activatable fibrinolysis inhibitor activation peptide shows association with all major subtypes of ischemic stroke and with TAFI gene variation. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2007**, 27, 955-62	9.4	60
214	The role of thrombin activatable fibrinolysis inhibitor in arterial thrombosis at a young age: the ATTAC study. *Journal of Thrombosis and Haemostasis*, **2009**, 7, 919-27	15.4	58
213	Plasminogen activator inhibitor-1. *Current Medicinal Chemistry*, **2004**, 11, 2323-34	4.3	58
212	The Market of Biopharmaceutical Medicines: A Snapshot of a Diverse Industrial Landscape. *Frontiers in Pharmacology*, **2017**, 8, 314	5.6	56
211	Modulation of Plasminogen Activator Inhibitor 1 by Triton X-100 Identification of Two Consecutive Conformational Transitions. *Thrombosis and Haemostasis*, **1998**, 80, 286-291	7	53
210	Accelerated conversion of human plasminogen activator inhibitor-1 to its latent form by antibody binding. *Journal of Biological Chemistry*, **1999**, 274, 17511-7	5.4	53
209	Conformational studies on plasminogen activator inhibitor (PAI-1) in active, latent, substrate, and cleaved forms. *Biochemistry*, **1995**, 34, 1064-9	3.2	53
208	Hyperthermia inhibits angiogenesis by a plasminogen activator inhibitor 1-dependent mechanism. *Cancer Research*, **2003**, 63, 1500-7	10.1	53
207	Immunogenicity of immunomodulatory, antibody-based, oncology therapeutics **2019**, 7, 105		52
206	Comparative thrombolytic and immunogenic properties of staphylokinase and streptokinase. *Fibrinolysis*, **1992**, 6, 232-242		51
205	Prevention of Renal Fibrin Deposition in Endotoxin-induced DIC through Inhibition of PAI-1. *Thrombosis and Haemostasis*, **2000**, 84, 65-70	7	49
204	Overcoming Barriers to the Market Access of Biosimilars in the European Union: The Case of Biosimilar Monoclonal Antibodies. *Frontiers in Pharmacology*, **2016**, 7, 193	5.6	48
203	Inactivation of plasminogen activator inhibitor-1 by specific proteolysis with stromelysin-1 (MMP-3). *Journal of Biological Chemistry*, **2000**, 275, 37645-50	5.4	47
202	Importance of the hinge region between alpha-helix F and the main part of serpins, based upon identification of the epitope of plasminogen activator inhibitor type 1 neutralizing antibodies. *Journal of Biological Chemistry*, **2000**, 275, 6375-80	5.4	46

201	Recombinant staphylokinase variants with altered immunoreactivity. I: Construction and characterization. *Circulation*, **1996**, 94, 197-206	16.7	46
200	The Efficacy, Safety, and Immunogenicity of Switching Between Reference Biopharmaceuticals and Biosimilars: A Systematic Review. *Clinical Pharmacology and Therapeutics*, **2020**, 108, 734-755	6.1	45
199	Generation of monoclonal antibodies against autologous proteins in gene-inactivated mice. *Journal of Biological Chemistry*, **1995**, 270, 8397-400	5.4	44
198	Correlations between t-PA and PAI-1 antigen and activity and t-PA/PAI-1 complexes in plasma of control subjects and of patients with increased t-PA or PAI-1 levels. *Thrombosis Research*, **1990**, 60, 509-16	8.2	44
197	Dose-dependent modulation of choroidal neovascularization by plasminogen activator inhibitor type I: implications for clinical trials. *Investigative Ophthalmology and Visual Science*, **2003**, 44, 2791-7		43
196	Biochemical importance of glycosylation of plasminogen activator inhibitor-1. *Thrombosis and Haemostasis*, **2003**, 90, 206-17	7	42
195	Innovative thrombolytic strategy using a heterodimer diabody against TAFI and PAI-1 in mouse models of thrombosis and stroke. *Blood*, **2015**, 125, 1325-32	2.2	41
194	Identification of a bacterial inhibitor against g-type lysozyme. *Cellular and Molecular Life Sciences*, **2011**, 68, 1053-64	10.3	40
193	Modulation of TAFI function through different pathways--implications for the development of TAFI inhibitors. *Journal of Thrombosis and Haemostasis*, **2005**, 3, 2745-53	15.4	40
192	Harmonization of Infliximab and Anti-Infliximab Assays Facilitates the Comparison Between Originators and Biosimilars in Clinical Samples. *Inflammatory Bowel Diseases*, **2016**, 22, 969-75	4.5	39
191	Extending the capabilities of targeted molecular dynamics: simulation of a large conformational transition in plasminogen activator inhibitor 1. *Protein Science*, **2001**, 10, 798-808	6.3	38
190	Factor VII-activating protease promotes the proteolysis and inhibition of tissue factor pathway inhibitor. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2012**, 32, 427-33	9.4	37
189	Generation of a Highly Specific Monoclonal Anti-Infliximab Antibody for Harmonization of TNF-Coated Infliximab Assays. *Therapeutic Drug Monitoring*, **2015**, 37, 479-85	3.2	36
188	Development of a universal anti-adalimumab antibody standard for interlaboratory harmonization. *Therapeutic Drug Monitoring*, **2014**, 36, 669-73	3.2	36
187	Generation and characterization of inhibitory nanobodies towards thrombin activatable fibrinolysis inhibitor. *Journal of Thrombosis and Haemostasis*, **2010**, 8, 1302-12	15.4	36
186	Development of ELISAs measuring the extent of TAFI activation. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2006**, 26, 423-8	9.4	36
185	Inhibition of Thrombin-Activatable Fibrinolysis Inhibitor and Plasminogen Activator Inhibitor-1 Reduces Ischemic Brain Damage in Mice. *Stroke*, **2016**, 47, 2419-22	6.7	35
184	Evidence for a pre-latent form of the serpin plasminogen activator inhibitor-1 with a detached beta-strand 1C. *Journal of Biological Chemistry*, **2006**, 281, 36071-81	5.4	34

183	In vitro reductive activation of nitroimidazoles. *Biochemical Pharmacology*, **1986**, 35, 59-61	6	34
182	State of play and clinical prospects of antibody gene transfer. *Journal of Translational Medicine*, **2017**, 15, 131	8.5	33
181	Urokinase-type plasminogen activator promotes paracellular transmigration of neutrophils via Mac-1, but independently of urokinase-type plasminogen activator receptor. *Circulation*, **2011**, 124, 1848-59	16.7	33
180	Evaluation of the profibrinolytic properties of an anti-TAFI monoclonal antibody in a mouse thromboembolism model. *Blood*, **2011**, 117, 4615-22	2.2	32
179	Lysozyme inhibitor conferring bacterial tolerance to invertebrate type lysozyme. *Cellular and Molecular Life Sciences*, **2010**, 67, 1177-88	10.3	32
178	Proteinase specificity and functional diversity in point mutants of plasminogen activator inhibitor 1. *Journal of Biological Chemistry*, **1997**, 272, 12662-6	5.4	32
177	An echistatin-like Arg-Gly-Asp (RGD)-containing sequence in the heavy chain CDR3 of a murine monoclonal antibody that inhibits human platelet glycoprotein IIb/IIIa function. *British Journal of Haematology*, **1994**, 87, 562-71	4.5	32
176	Biosimilarity Versus Manufacturing Change: Two Distinct Concepts. *Pharmaceutical Research*, **2016**, 33, 261-8	4.5	31
175	The arrival of biosimilar monoclonal antibodies in oncology: clinical studies for trastuzumab biosimilars. *British Journal of Cancer*, **2019**, 121, 199-210	8.7	31
174	Activation of both coagulation and fibrinolysis in childhood hemolytic uremic syndrome. *Kidney International*, **1998**, 54, 1324-30	9.9	31
173	Recombinant plasminogen activator inhibitor-1 reverses the bleeding tendency associated with the combined administration of tissue-type plasminogen activator and aspirin in rabbits. *Journal of Clinical Investigation*, **1989**, 84, 586-91	15.9	30
172	Nonmedical Switching From Originators to Biosimilars: Does the Nocebo Effect Explain Treatment Failures and Adverse Events in Rheumatology and Gastroenterology?. *Rheumatology and Therapy*, **2020**, 7, 35-64	4.4	29
171	The distal hinge of the reactive site loop and its proximity: a target to modulate plasminogen activator inhibitor-1 activity. *Journal of Biological Chemistry*, **2001**, 276, 44912-8	5.4	29
170	Mechanisms of conversion of plasminogen activator inhibitor 1 from a suicide inhibitor to a substrate by monoclonal antibodies. *Journal of Biological Chemistry*, **2002**, 277, 43858-65	5.4	29
169	Characterization and Comparative Evaluation of a Novel PAI-1 Inhibitor. *Thrombosis and Haemostasis*, **2002**, 88, 137-143	7	28
168	His374 of wheat endoxylanase inhibitor TAXI-I stabilizes complex formation with glycoside hydrolase family 11 endoxylanases. *FEBS Journal*, **2005**, 272, 5872-82	5.7	28
167	Identification of a Functional Epitope in Plasminogen Activator Inhibitor-1, not Localized in the Reactive Center Loop. *Thrombosis and Haemostasis*, **1998**, 79, 597-601	7	28
166	Biosimilars: controversies as illustrated by rhGH. *Current Medical Research and Opinion*, **2010**, 26, 1219-29	2.5	27

165	A European perspective on the market accessibility of biosimilars. *Biosimilars (Auckland, New Zealand)*, **2012**, 33		27
164	Reciprocal regulation of tissue-type and urokinase-type plasminogen activators in the differentiation of murine preadipocyte line 3T3-L1 and the hormonal regulation of fibrinolytic factors in the mature adipocytes. *Journal of Cellular Physiology*, **2001**, 189, 72-8	7	27
163	Reactive site-dependent phenotypic alterations in plasminogen activator inhibitor-1 transgenic mice. *Journal of Thrombosis and Haemostasis*, **2007**, 5, 1500-8	15.4	26
162	Generation of a stable activated thrombin activable fibrinolysis inhibitor variant. *Journal of Biological Chemistry*, **2006**, 281, 15878-83	5.4	26
161	A Camelid-derived Antibody Fragment Targeting the Active Site of a Serine Protease Balances between Inhibitor and Substrate Behavior. *Journal of Biological Chemistry*, **2016**, 291, 15156-68	5.4	26
160	The story of the serpin plasminogen activator inhibitor 1: is there any need for another mutant?. *Thrombosis and Haemostasis*, **2004**, 92, 898-924	7	24
159	Characterization of common neoantigenic epitopes generated in plasminogen activator inhibitor-1 after cleavage of the reactive center loop or after complex formation with various serine proteinases. *FEBS Letters*, **1995**, 376, 243-6	3.8	24
158	A model of the reactive form of plasminogen activator inhibitor-1. *Journal of Structural Biology*, **1994**, 113, 239-45	3.4	24
157	Dynamic structural and functional relationships in recombinant plasminogen activator inhibitor-1 (rPAI-1). *BBA - Proteins and Proteomics*, **1993**, 1202, 221-9		24
156	Thrombin activatable fibrinolysis inhibitor. *Hamostaseologie*, **2011**, 31, 165-6, 168-73	1.9	24
155	Targeting of plasminogen activator inhibitor 1 improves fibrinolytic therapy for tetracycline-induced pleural injury in rabbits. *American Journal of Respiratory Cell and Molecular Biology*, **2015**, 52, 429-37	5.7	23
154	Defective TAFI activation in hemophilia A mice is a major contributor to joint bleeding. *Blood*, **2018**, 132, 1593-1603	2.2	23
153	The roles of selected arginine and lysine residues of TAFI (Pro-CPU) in its activation to TAFIa by the thrombin-thrombomodulin complex. *Journal of Biological Chemistry*, **2009**, 284, 7059-67	5.4	23
152	Elucidation of the epitope of a latency-inducing antibody: identification of a new molecular target for PAI-1 inhibition. *Thrombosis and Haemostasis*, **2003**, 90, 52-58	7	23
151	Discovery of a novel conformational equilibrium in urokinase-type plasminogen activator. *Scientific Reports*, **2017**, 7, 3385	4.9	22
150	Announcing a TAFIa mutant with a 180-fold increased half-life and concomitantly a strongly increased antifibrinolytic potential. *Journal of Thrombosis and Haemostasis*, **2007**, 5, 418-20	15.4	22
149	Characterization of rat thrombin-activatable fibrinolysis inhibitor (TAFI)--a comparative study assessing the biological equivalence of rat, murine and human TAFI. *Journal of Thrombosis and Haemostasis*, **2006**, 4, 2470-7	15.4	22
148	Crystallization and X-ray diffraction data of the cleaved form of plasminogen activator inhibitor-1. *Proteins: Structure, Function and Bioinformatics*, **1995**, 23, 118-21	4.2	22

147	Base specific interaction of reductively activated nitroimidazoles with DNA. *FEBS Letters*, **1983**, 164, 145-8	3.8	22
146	Thrombin activatable fibrinolysis inhibitor: a putative target to enhance fibrinolysis. *Seminars in Thrombosis and Hemostasis*, **2013**, 39, 365-72	5.3	21
145	A peptide accelerating the conversion of plasminogen activator inhibitor-1 to an inactive latent state. *Molecular Pharmacology*, **2008**, 74, 641-53	4.3	21
144	Biochemical importance of glycosylation in thrombin activatable fibrinolysis inhibitor. *Circulation Research*, **2008**, 102, 295-301	15.7	21
143	Effect of Stabilizing versus Destabilizing Interactions on Plasminogen Activator Inhibitor-1. *Thrombosis and Haemostasis*, **2000**, 84, 871-875	7	21
142	Polarographic evidence for the interaction of reduced nitroimidazole derivatives with DNA bases. *Journal of the Chemical Society Faraday Transactions I*, **1987**, 83, 257		21
141	Targeting PAI-1 in Cardiovascular Disease: Structural Insights Into PAI-1 Functionality and Inhibition. *Frontiers in Cardiovascular Medicine*, **2020**, 7, 622473	5.4	21
140	TAFIa inhibiting nanobodies as profibrinolytic tools and discovery of a new TAFIa conformation. *Journal of Thrombosis and Haemostasis*, **2011**, 9, 2268-77	15.4	20
139	Discovery of novel mechanisms and molecular targets for the inhibition of activated thrombin activatable fibrinolysis inhibitor. *Journal of Thrombosis and Haemostasis*, **2008**, 6, 1892-9	15.4	20
138	The importance of helix F in plasminogen activator inhibitor-1. *BBA - Proteins and Proteomics*, **2000**, 1476, 20-6		20
137	A Narrative Review on Plasminogen Activator Inhibitor-1 and Its (Patho)Physiological Role: To Target or Not to Target?. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	20
136	Novel or expanding current targets in fibrinolysis. *Drug Discovery Today*, **2014**, 19, 1476-82	8.8	19
135	Maximal PAI-1 inhibition in vivo requires neutralizing antibodies that recognize and inhibit glycosylated PAI-1. *Thrombosis Research*, **2012**, 129, e126-33	8.2	19
134	The hyperfibrinolytic state of mice with combined thrombin-activatable fibrinolysis inhibitor (TAFI) and plasminogen activator inhibitor-1 gene deficiency is critically dependent on TAFI deficiency. *Journal of Thrombosis and Haemostasis*, **2012**, 10, 2555-62	15.4	19
133	Identification and characterisation of monoclonal antibodies that impair the activation of human thrombin activatable fibrinolysis inhibitor through different mechanisms. *Thrombosis and Haemostasis*, **2011**, 106, 90-101	7	19
132	Plant pectin methylesterase and its inhibitor from kiwi fruit: Interaction analysis by surface plasmon resonance. *Food Chemistry*, **2010**, 121, 207-214	8.5	19
131	Pathophysiology of fibrinolysis. *Best Practice and Research: Clinical Haematology*, **1995**, 8, 329-43		19
130	Additivity in effects of vitronectin and monoclonal antibodies against alpha-helix F of plasminogen activator inhibitor-1 on its reactions with target proteinases. *Journal of Biological Chemistry*, **2005**, 280, 1482-9	5.4	18

129	An Enzyme-Linked Immunosorbent Assay for Urokinase-Type Plasminogen Activator (u-PA) and Mutants and Chimeras Containing the Serine Protease Domain of u-PA. *Thrombosis and Haemostasis* , **1992**, 67, 095-100	7	18
128	Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 1-Biosimilar and Originator Infliximab in the Hospital Setting. *BioDrugs*, **2019**, 33, 285-297	7.9	17
127	Monoclonal antibodies targeting the antifibrinolytic activity of activated thrombin-activatable fibrinolysis inhibitor but not the anti-inflammatory activity on osteopontin and C5a. *Journal of Thrombosis and Haemostasis*, **2013**, 11, 2137-47	15.4	17
126	Evaluation of the mechanism of inactivation of plasminogen activator inhibitor-1 by monoclonal antibodies using a stable variant. *Fibrinolysis and Proteolysis*, **1998**, 12, 277-282		17
125	Elucidation of a novel epitope of a substrate-inducing monoclonal antibody against the serpin PAI-1. *Journal of Thrombosis and Haemostasis*, **2003**, 1, 1028-33	15.4	17
124	Measurement of different forms of plasminogen activator inhibitor 1(PAI-1) using various monoclonal antibody-based enzyme-linked immunosorbent assays. *Fibrinolysis*, **1990**, 4, 132-133		17
123	Monoclonal Antibody Biosimilars in Oncology: Critical Appraisal of Available Data on Switching. *Clinical Therapeutics*, **2018**, 40, 798-809.e2	3.5	16
122	Subtle structural differences between human and mouse PAI-1 reveal the basis for biochemical differences. *Journal of Structural Biology*, **2010**, 171, 95-101	3.4	16
121	Identification of positively charged residues contributing to the stability of plasminogen activator inhibitor 1. *FEBS Letters*, **1997**, 415, 192-5	3.8	16
120	Bispecific targeting of thrombin activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 by a heterodimer diabody. *Journal of Thrombosis and Haemostasis*, **2008**, 6, 1884-91	15.4	16
119	Importance of N-Terminal Residues in Plasminogen Activator Inhibitor 1 on its Antibody Induced Latency Transition. *Thrombosis and Haemostasis*, **2002**, 88, 288-293	7	16
118	Identification of a target site in plasminogen activator inhibitor-1 that allows neutralization of its inhibitor properties concomitant with an allosteric up-regulation of its antiadhesive properties. *Journal of Biological Chemistry*, **2001**, 276, 26243-8	5.4	16
117	Prolonged expression and anti-tumor response of DNA-based anti-HER2 antibodies. *Oncotarget*, **2018**, 9, 13623-13636	3.3	16
116	Nebulized fibrinolytic agents improve pulmonary fibrinolysis but not inflammation in rat models of direct and indirect acute lung injury. *PLoS ONE*, **2013**, 8, e55262	3.7	15
115	Rational design of complex formation between plasminogen activator inhibitor-1 and its target proteinases. *Journal of Structural Biology*, **1997**, 118, 236-42	3.4	15
114	Modulation of serpin reaction through stabilization of transient intermediate by ligands bound to alpha-helix F. *Journal of Biological Chemistry*, **2007**, 282, 26306-15	5.4	15
113	Migration of the activation peptide of thrombin-activatable fibrinolysis inhibitor (TAFI) during SDS-polyacrylamide gel electrophoresis. *Journal of Thrombosis and Haemostasis*, **2004**, 2, 780-4	15.4	15
112	Molecular forms of plasminogen activator inhibitor-1 (PAI-1) and tissue-type plasminogen activator (t-PA) in human plasma. *Thrombosis Research*, **1991**, 62, 275-85	8.2	15

111	Platelet activation and high tissue factor level predict acute stent thrombosis in pig coronary arteries: prothrombogenic response of drug-eluting or bare stent implantation within the first 24 hours. *Thrombosis and Haemostasis*, **2006**, 96, 202-9	7	15
110	High thrombin activatable fibrinolysis inhibitor levels are associated with an increased risk of premature peripheral arterial disease. *Thrombosis Research*, **2011**, 127, 254-8	8.2	14
109	Targeting the autolysis loop of urokinase-type plasminogen activator with conformation-specific monoclonal antibodies. *Biochemical Journal*, **2011**, 438, 39-51	3.8	14
108	High quality structure of cleaved PAI-1-stab. *Journal of Structural Biology*, **2009**, 165, 126-32	3.4	14
107	Biotherapeutics in the era of biosimilars: what really matters is patient safety. *Drug Safety*, **2007**, 30, 1087-92	5.1	14
106	Comparative evaluation of stable TAFIa variants: importance of alpha-helix 9 and beta-sheet 11 for TAFIa (in)stability. *Journal of Thrombosis and Haemostasis*, **2007**, 5, 2105-12	15.4	14
105	Function-stabilizing mechanism of plasminogen activator inhibitor type 1 induced upon binding to alpha1-acid glycoprotein. *Biochemistry*, **2005**, 44, 12384-90	3.2	14
104	The road from development to approval: evaluating the body of evidence to confirm biosimilarity. *Rheumatology*, **2017**, 56, iv4-iv13	3.9	13
103	Active PAI-1 as marker for venous thromboembolism: case-control study using a comprehensive panel of PAI-1 and TAFI assays. *Thrombosis Research*, **2014**, 134, 1097-102	8.2	13
102	Identification of a novel, nanobody-induced, mechanism of TAFI inactivation and its in vivo application. *Journal of Thrombosis and Haemostasis*, **2014**, 12, 229-36	15.4	13
101	Characterization of a panel of monoclonal antibodies toward mouse PAI-1 that exert a significant profibrinolytic effect in vivo. *Thrombosis Research*, **2011**, 128, 68-76	8.2	13
100	Enhancement of endogenous fibrinolysis does not reduce local fibrin deposition, but modulates inflammation upon intestinal ischemia and reperfusion. *Thrombosis and Haemostasis*, **2004**, 91, 497-505	7	13
99	Tryptophan properties in fluorescence and functional stability of plasminogen activator inhibitor 1. *Biophysical Journal*, **2003**, 85, 501-10	2.9	13
98	Generation and in vitro characterisation of inhibitory nanobodies towards plasminogen activator inhibitor 1. *Thrombosis and Haemostasis*, **2016**, 116, 1032-1040	7	13
97	Elucidation of the molecular mechanisms of two nanobodies that inhibit thrombin-activatable fibrinolysis inhibitor activation and activated thrombin-activatable fibrinolysis inhibitor activity. *Journal of Thrombosis and Haemostasis*, **2016**, 14, 1629-38	15.4	13
96	Demystifying biosimilars: development, regulation and clinical use. *Future Oncology*, **2019**, 15, 777-790	3.6	13
95	Biosimilars - terms of use. *Current Medical Research and Opinion*, **2015**, 31, 2325-30	2.5	12
94	Remarkable stabilization of plasminogen activator inhibitor 1 in a "molecular sandwich" complex. *Biochemistry*, **2013**, 52, 4697-709	3.2	12

93	Cloning of a single-chain variable fragment (scFv) switching active plasminogen activator inhibitor-1 to substrate. *Gene*, **1997**, 189, 83-8	3.8	12
92	Immobilization of the distal hinge in the labile serpin plasminogen activator inhibitor 1: identification of a transition state with distinct conformational and functional properties. *Journal of Biological Chemistry*, **2003**, 278, 23899-905	5.4	12
91	Inhibition of plasminogen activator inhibitor-1: antibody fragments and their unique sequences as a tool for the development of profibrinolytic drugs. *Journal of Thrombosis and Haemostasis*, **2004**, 2, 298-305	15.4	12
90	Expanding a Portfolio of (FO-) SPR Surface Chemistries with the Co(III)-NTA Oriented Immobilization of His-Tagged Bioreceptors for Applications in Complex Matrices. *ACS Sensors*, **2020**, 5, 960-969	9.2	11
89	Activation of the zymogen to urokinase-type plasminogen activator is associated with increased interdomain flexibility. *Journal of Molecular Biology*, **2011**, 411, 417-29	6.5	11
88	Development and evaluation of monoclonal antibodies as probes to assess the differences between two tomato pectin methylesterase isoenzymes. *Journal of Immunological Methods*, **2009**, 349, 18-27	2.5	11
87	Redirection of the reaction between activated protein C and a serpin to the substrate pathway. *Thrombosis Research*, **2008**, 122, 397-404	8.2	11
86	Enhanced expression of plasminogen activator inhibitor-1 by dedifferentiated thyrocytes. *Biochemical and Biophysical Research Communications*, **2002**, 295, 737-43	3.4	11
85	Amplified endogenous plasmin activity resolves acute thrombotic thrombocytopenic purpura in mice. *Journal of Thrombosis and Haemostasis*, **2017**, 15, 2432-2442	15.4	10
84	DNA-Based Delivery of Checkpoint Inhibitors in Muscle and Tumor Enables Long-Term Responses with Distinct Exposure. *Molecular Therapy*, **2020**, 28, 1068-1077	11.7	10
83	Plasmin and the thrombin-thrombomodulin complex both contribute to thrombin-activatable fibrinolysis inhibitor activation in whole blood model thrombi. *Journal of Thrombosis and Haemostasis*, **2013**, 11, 190-2	15.4	10
82	Advances in understanding pectin methylesterase inhibitor in kiwi fruit: an immunological approach. *Planta*, **2011**, 233, 287-98	4.7	10
81	Bioavailability of different artemisinin tablet formulations in rabbit plasma--correlation with results obtained by an in vitro dissolution method. *Journal of Pharmaceutical and Biomedical Analysis*, **1997**, 16, 185-9	3.5	10
80	Thrombin-activatable fibrinolysis inhibitor is associated with severity and outcome of severe meningococcal infection in children. *Journal of Thrombosis and Haemostasis*, **2008**, 6, 268-76	15.4	10
79	Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 2-Biosimilar and Originator Etanercept in the Outpatient Setting. *BioDrugs*, **2019**, 33, 299-306	7.9	9
78	Targeting plasminogen activator inhibitor-1 in tetracycline-induced pleural injury in rabbits. *American Journal of Physiology - Lung Cellular and Molecular Physiology*, **2018**, 314, L54-L68	5.8	9
77	Bridging the Clinical Gap for DNA-Based Antibody Therapy Through Translational Studies in Sheep. *Human Gene Therapy*, **2019**, 30, 1431-1443	4.8	9
76	Convalescent plasma levels of TAFI activation peptide predict death and recurrent vascular events in ischemic stroke survivors. *Journal of Thrombosis and Haemostasis*, **2012**, 10, 725-7	15.4	9

75	Use of mouse models to study plasminogen activator inhibitor-1. *Methods in Enzymology*, **2011**, 499, 77-104	1.7	9
74	Characterization of plasminogen activator inhibitor 1 mutants containing the P13 to P10 region of ovalbumin or antithrombin III: evidence that the P13 residue contributes significantly to the active to substrate transition. *BBA - Proteins and Proteomics*, **1998**, 1387, 291-7		9
73	Development of anti-matrix metalloproteinase-2 (MMP-2) nanobodies as potential therapeutic and diagnostic tools. *Nanomedicine: Nanotechnology, Biology, and Medicine*, **2020**, 24, 102103	6	9
72	Haemostatic biomarkers are associated with long-term recurrent vascular events after ischaemic stroke. *Thrombosis and Haemostasis*, **2016**, 116, 537-43	7	9
71	Increased zymogen activity of thrombin-activatable fibrinolysis inhibitor prolongs clot lysis. *Journal of Thrombosis and Haemostasis*, **2012**, 10, 1091-9	15.4	8
70	The Occurrence of Thrombosis in Inflammatory Bowel Disease Is Reflected in the Clot Lysis Profile. *Inflammatory Bowel Diseases*, **2015**, 21, 2540-8	4.5	8
69	In vitro and in vivo characterisation of the profibrinolytic effect of an inhibitory anti-rat TAFI nanobody. *Thrombosis and Haemostasis*, **2014**, 111, 824-32	7	8
68	Species-dependent molecular drug targets in plasminogen activator inhibitor-1 (PAI-1). *Thrombosis and Haemostasis*, **2009**, 102, 609-10	7	8
67	The conversion of active to latent plasminogen activator inhibitor-1 is an energetically silent event. *Biophysical Journal*, **2005**, 88, 2848-54	2.9	8
66	Immunological Quantitation of Rabbit Plasminogen Activator Inhibitor-1 in Biological Samples. *Thrombosis and Haemostasis*, **1999**, 82, 1510-1515	7	8
65	Influence of oral intake of retinoids on the human plasma fibrinolytic system. *Fibrinolysis*, **1993**, 7, 347-351		8
64	Induction of t-PA Synthesis with intravenous bolus injection of vitamin A palmitate in vitamin a deficient rats. *Fibrinolysis*, **1992**, 6, 243-249		8
63	Hydrogenosomal ATP:AMP phosphotransferase of Trichomonas vaginalis. *Comparative Biochemistry and Physiology Part B: Comparative Biochemistry*, **1987**, 88, 575-80		8
62	Molecular mechanism of two nanobodies that inhibit PAI-1 activity reveals a modulation at distinct stages of the PAI-1/plasminogen activator interaction. *Journal of Thrombosis and Haemostasis*, **2020**, 18, 681-692	15.4	8
61	Thrombin Activatable Fibrinolysis Inhibitor (TAFI): An Updated Narrative Review. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	8
60	Biopharmaceuticals: Reference Products and Biosimilars to Treat Inflammatory Diseases. *Therapeutic Drug Monitoring*, **2017**, 39, 308-315	3.2	7
59	A Genome-wide Study of Common and Rare Genetic Variants Associated with Circulating Thrombin Activatable Fibrinolysis Inhibitor. *Thrombosis and Haemostasis*, **2018**, 118, 298-308	7	7
58	Systemic inhibition and liver-specific over-expression of PAI-1 failed to improve survival in all-inclusive populations or homogenous cohorts of CLP mice. *Journal of Thrombosis and Haemostasis*, **2014**, 12, 958-69	15.4	7

57	Letter: dry blood spots for anti-TNF treatment monitoring in IBD. *Alimentary Pharmacology and Therapeutics*, **2013**, 37, 1024-5	6.1	7
56	Evaluation of the profibrinolytic properties of a bispecific antibody-based inhibitor against human and mouse thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1. *Journal of Thrombosis and Haemostasis*, **2013**, 11, 2069-71	15.4	7
55	Identification of functional synergism between monoclonal antibodies. Application to the enhancement of plasminogen activator inhibitor-1 neutralizing effects. *FEBS Letters*, **1997**, 416, 373-6	3.8	7
54	Study of recombinant antibody fragments and PAI-1 complexes combining protein-protein docking and results from site-directed mutagenesis. *Structure*, **2007**, 15, 1105-16	5.2	7
53	Elucidation of the epitope of a latency-inducing antibody: identification of a new molecular target for PAI-1 inhibition. *Thrombosis and Haemostasis*, **2003**, 90, 52-8	7	7
52	Comparative study of inhibitory antibody derivatives towards thrombin activatable fibrinolysis inhibitor. *Thrombosis and Haemostasis*, **2009**, 102, 69-75	7	6
51	Effect of Reteplase and PAI-1 antibodies on postoperative adhesion formation in a laparoscopic mouse model. *Surgical Endoscopy and Other Interventional Techniques*, **2009**, 23, 1018-25	5.2	6
50	Protonation state of a single histidine residue contributes significantly to the kinetics of the reaction of plasminogen activator inhibitor-1 with tissue-type plasminogen activator. *Journal of Biological Chemistry*, **2004**, 279, 23007-13	5.4	6
49	Cloning and paratope analysis of an antibody fragment, a rational approach for the design of a PAI-1 inhibitor. *Journal of Thrombosis and Haemostasis*, **2004**, 2, 289-97	15.4	6
48	Glycosylation dependent conformational transitions in plasminogen activator inhibitor-1: evidence for the presence of two active conformations. *Fibrinolysis and Proteolysis*, **2000**, 14, 58-64		6
47	Clearance of plasmin-PN-1 complexes by vascular smooth muscle cells in human aneurysm of the ascending aorta. *Cardiovascular Pathology*, **2018**, 32, 15-25	3.8	5
46	Expression, purification, and characterization of recombinant rat plasminogen activator inhibitor-1. *Fibrinolysis and Proteolysis*, **1997**, 11, 37-43		5
45	Elucidation of the paratope of scFv-8H9D4, a PAI-1 neutralizing antibody derivative. *Thrombosis and Haemostasis*, **2003**, 89, 74-82	7	5
44	Immunoassays for the Quantitation of Porcine PAI-1 Antigen and Activity in Biological Fluid Samples. *Thrombosis and Haemostasis*, **2000**, 84, 1082-1086	7	5
43	Immunological methods to study the fibrinolytic system. *Fibrinolysis*, **1993**, 7, 9-10		5
42	Quantitation of Vervet Monkey (Chlorocebus aethiops) plasminogen activator inhibitor-1 in plasma and platelets. *Thrombosis and Haemostasis*, **2006**, 95, 902-903	7	5
41	Importance of manufacturing consistency of the glycosylated monoclonal antibody adalimumab (Humira) and potential impact on the clinical use of biosimilars. *GaBI Journal*, **2016**, 5, 70-73	3.1	5
40	Structural Insights into the Mechanism of a Nanobody That Stabilizes PAI-1 and Modulates Its Activity. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	5

39	Generation of a stable thrombin-activatable fibrinolysis inhibitor deletion mutant exerting full carboxypeptidase activity without activation. *Journal of Thrombosis and Haemostasis*, **2015**, 13, 1084-9	15.4	4
38	Suppression of plasminogen activator inhibitor 1 (PAI-1) activity levels in rats by monoclonal antibodies. *Fibrinolysis and Proteolysis*, **1998**, 12, 335-339		4
37	Structural determinants in the stability of the serpin/proteinase complex. *Biochemical and Biophysical Research Communications*, **2003**, 307, 529-34	3.4	4
36	DNA-based delivery of anti-DR5 Nanobodies improves exposure and anti-tumor efficacy over protein-based administration. *Cancer Gene Therapy*, **2021**, 28, 828-838	5.4	4
35	The rise of oncology biosimilars: from process to promise. *Future Oncology*, **2019**, 15, 3255-3265	3.6	3
34	Tissue Exposure does not Explain Non-Response in Ulcerative Colitis Patients with Adequate Serum Vedolizumab Concentrations. *Journal of Crohnks and Colitis*, **2021**, 15, 988-993	1.5	3
33	Development of an immunological toolbox to detect endogenous and exogenous pectin methylesterase in plant-based food products. *Food Research International*, **2011**, 44, 931-939	7	3
32	Glycosylation influences the stability of human plasminogen activator inhibitor-1. *Blood Coagulation and Fibrinolysis*, **2012**, 23, 570-2	1	3
31	Conformational (in)stability of rat vs. human activated thrombin activatable fibrinolysis inhibitor. *Journal of Thrombosis and Haemostasis*, **2008**, 6, 1426-8	15.4	3
30	Site-directed targeting of plasminogen activator inhibitor-1 as an example for a novel approach in rational drug design. *Journal of Biological Chemistry*, **2004**, 279, 20447-50	5.4	3
29	Plasminogen activator inhibitor 1 (PAI-1) in its active conformation: crystallization and preliminary X-ray diffraction data. *Acta Crystallographica Section D: Biological Crystallography*, **1999**, 55, 574-6		3
28	Structural Insight into the Two-Step Mechanism of PAI-1 Inhibition by Small Molecule TM5484. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	3
27	Lys 42/43/44 and Arg 12 of thrombin-activable fibrinolysis inhibitor comprise a thrombomodulin exosite essential for its antifibrinolytic potential. *Thrombosis and Haemostasis*, **2017**, 117, 1509-1517	7	2
26	Development of a liquid chromatography/mass spectrometry assay for the bacterial transglycosylation reaction through measurement of Lipid II. *Electrophoresis*, **2015**, 36, 2841-2849	3.6	2
25	Construction and characterization of plasminogen activator inhibitor-1 mutants in which part of the active site loop is deleted. *Fibrinolysis and Proteolysis*, **1997**, 11, 265-271		2
24	Induction of conformational changes within crystals of plasminogen activator inhibitor-1 (PAI-1). *Fibrinolysis and Proteolysis*, **1999**, 13, 203-207		2
23	Prevention of Premature Fibrinolysis and Reduction of Bleeding in Vivo in Hemophilia with Inhibitors By a Stabilized TAFI Variant. *Blood*, **2014**, 124, 694-694	2.2	2
22	Intratumoral DNA-based delivery of checkpoint-inhibiting antibodies and interleukin 12 triggers T cell infiltration and anti-tumor response. *Cancer Gene Therapy*, **2021**,	5.4	2

21	Electroporation outperforms in vivo-jetPEI for intratumoral DNA-based reporter gene transfer. *Scientific Reports*, **2020**, 10, 19532	4.9	2
20	Knowledge and perception of biosimilars in ambulatory care: a survey among Belgian community pharmacists and physicians. *Journal of Pharmaceutical Policy and Practice*, **2021**, 14, 53	3.2	2
19	Population pharmacokinetic-pharmacodynamic model-based exploration of alternative ustekinumab dosage regimens for patients with Crohn's disease. *British Journal of Clinical Pharmacology*, **2021**,	3.8	2
18	Miniaturized single-cell technologies for monoclonal antibody discovery. *Lab on A Chip*, **2021**, 21, 3627-3654	7.2	2
17	Improved Potency and Safety of DNA-Encoded Antibody Therapeutics Through Plasmid Backbone and Expression Cassette Engineering. *Human Gene Therapy*, **2021**, 32, 1200-1209	4.8	2
16	Quantitation of Vervet monkey (Chlorocebus aethiops) plasminogen activator inhibitor-1 in plasma and platelets. *Thrombosis and Haemostasis*, **2006**, 95, 902-3	7	2
15	Long-term in vivo expression of trastuzumab following intramuscular electrotransfer of the encoding DNA in mice **2015**, 3,		1
14	Immunological toolbox available for in situ exploration of pectic homogalacturonan and its modifying enzymes in fruits and vegetables and their derived food products. *Innovative Food Science and Emerging Technologies*, **2012**, 15, 72-80	6.8	1
13	Monoclonal antibodies: indications, budget impact and use. *Journal of Pharmaceutical Health Services Research*, **2010**, 1, 123-130	1	1
12	Comparative analysis of the proteinase specificity in wild-type and stabilized plasminogen activator inhibitor-1: evidence for contribution of intramolecular flexibility. *Biochemical and Biophysical Research Communications*, **2004**, 321, 746-51	3.4	1
11	Both plasma basic carboxypeptidases, carboxypeptidase B2 and carboxypeptidase N, regulate vascular leakage activity in mice. *Journal of Thrombosis and Haemostasis*, **2021**,	15.4	1
10	Plasminogen Activators Inhibitors **2003**, 47-66		1
9	Generation and characterization of monoclonal antibodies against the N-terminus of alpha-2-antiplasmin. *PLoS ONE*, **2018**, 13, e0196911	3.7	1
8	Regulatory Information and Guidance on Biosimilars and Their Use Across Europe: A Call for Strengthened One Voice Messaging.. *Frontiers in Medicine*, **2022**, 9, 820755	4.9	1
7	S62798, a potent TAFIa inhibitor, accelerates endogenous fibrinolysis in a murine model of pulmonary thromboembolism. *Thrombosis Research*, **2021**, 204, 81-87	8.2	0
6	Clot stability and fibrin deposition is strongly reduced in mice in which mouse TAFI is replaced by human TAFI. *Thrombosis Research*, **2014**, 133, 1166-8	8.2	
5	Various approaches to standardization and the importance of measurement accuracy. *Fibrinolysis*, **1996**, 10, 113-116		
4	Defective TAFI Activation in Hemophilia Exacerbates Vascular Remodeling in Hemophilic Arthropathy. *Blood*, **2016**, 128, 82-82	2.2	

3	Defective TAFI Activation in Hemophilia Worsens Joint Bleeding. *Blood*, **2016**, 128, 3752-3752	2.2
2	Prevention of Serpin Misfolding by RNA Aptamers. *Cell Chemical Biology*, **2016**, 23, 639-40	8.2
1	Selective neutralization of the serpin protease nexin-1 by a specific monoclonal antibody. *British Journal of Haematology*, **2016**, 172, 631-3	4.5